newsfilter
← Latest News
GlobeNewswire·

Immutep Announces Successful Completion of FDA Project Optimus Requirements

Confirmation of 30mg efti as optimal biological dose relevant for Immutep's oncology pipeline and potential future Biological License Applications (BLA)Registrational TACTI-004 (KEYNOTE-F91) Phase III trial in first line